High frequency of CD4 +CD25 -CD69 + T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants

Clinical Transplantation

Volumn 26, Issue 2, 2012, Pages

  Lu, Sheng Ye ^a   Huang, Xiao Jun ^a   Liu, Kai Yan ^a   Liu, Dai Hong ^a   Xu, Lan Ping ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic cell transplantation; Regulatory T cells

Indexed keywords

BASILIXIMAB; CD69 ANTIGEN; CYCLOSPORIN A; DEXAMETHASONE; METHOTREXATE; METHYLPREDNISOLONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84859852642     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01630.x     Document Type: Article

References (48)

1. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009: 114: 4327.
2. Lu DP, Dong L, Wu T et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006: 107: 3065.
3. Huang XJ, Liu DH, Liu KY et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006: 38: 291.
4. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991: 78: 2120.
5. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006: 24: 209.
6. Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005: 4: 351.
7. Buckner JH, Ziegler SF. Regulating the immune system: the induction of regulatory T cells in the periphery. Arthritis Res Ther 2004: 6: 215.
8. Jiang S, Lechler RI, He XS, Huang JF. Regulatory T cells and transplantation tolerance. Hum Immunol 2006: 67: 765.
9. Kiniwa Y, Miyahara Y, Wang HY et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007: 13: 6947.
10. Degauque N, Lair D, Braudeau C et al. Development of CD25- regulatory T cells following heart transplantation: evidence for transfer of long-term survival. Eur J Immunol 2007: 37: 147.
11. Issa F, Schiopu A, Wood KJ. Role of T cells in graft rejection and transplantation tolerance. Expert Rev Clin Immunol 2010: 6: 155.
12. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007: 109: 827.
13. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002: 99: 3493.
14. Adeegbe D, Bayer AL, Levy RB, Malek TR. Cutting edge: allogeneic CD4+CD25+Foxp3+ T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J Immunol 2006: 176: 7149.
15. Wang XN, Haniffa MA, Holtick U et al. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming. Transplantation 2009: 88: 188.
16. Rezvani K, Mielke S, Ahmadzadeh M et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006: 108: 1291.
17. Noel G, Bruniquel D, DeGuibert S et al. Regulatory CD4+CD25hi T cells conserve their function and phenotype after granulocyte colony-stimulating factor treatment in human hematopoietic stem cell transplantation. Hum Immunol 2008: 69: 329.
18. Noel G, Bruniquel D, Birebent B et al. Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4+CD25hiFoxp3+ regulatory T cells. Clin Immunol 2008: 129: 241.
19. Ermann J, Hoffmann P, Edinger M et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005: 105: 2220.
20. Taylor PA, Panoskaltsis-Mortari A, Swedin JM et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004: 104: 3804.
21. Schmidt-Hieber M, Fietz T, Knauf W et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005: 130: 568.
22. Ji SQ, Chen HR, Yan HM et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005: 36: 349.
23. Cahn JY, Bordigoni P, Tiberghien P et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995: 60: 939.
24. Blaise D, Olive D, Hirn M et al. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant 1991: 8: 105.
25. Feunou P, Poulin L, Habran C, Le Moine A, Goldman M, Braun MY. CD4+CD25+ and CD4+CD25- T cells act respectively as inducer and effector T suppressor cells in superantigen-induced tolerance. J Immunol 2003: 171: 3475.
26. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H. Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002: 168: 5558.
27. Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol 2000: 165: 3105.
28. Zeller JC, Panoskaltsis-Mortari A, Murphy WJ et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol 1999: 163: 3684.
29. Banovic T, MacDonald KP, Morris ES et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 2005: 106: 2206.
30. Visentainer JE, Lieber SR, Persoli LB et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 2003: 31: 1044.
31. Hattori H, Matsuzaki A, Suminoe A et al. Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplant 2002: 30: 665.
32. Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009: 182: 111.
33. Chang YJ, Zhao XY, Huo MR, Huang XJ. Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. J Clin Immunol 2009: 29: 696.
34. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974: 18: 295.
35. Huang XJ, Jiang Q, Chen H et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005: 36: 343.
36. Lu J, Xu LP, Huang XJ et al. [Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody]. Zhonghua Yi Xue Za Zhi 2003: 83: 216.
37. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009: 30: 636.
38. Ruzek MC, Waire JS, Hopkins D et al. Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood 2008: 111: 1726.
39. Coenen JJ, Koenen HJ, van Rijssen E et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007: 39: 537.
40. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004: 4: 665.
41. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004: 172: 6519.
42. Zhang H, Chua KS, Guimond M et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005: 11: 1238.
43. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006: 107: 2409.
44. Hsieh CS, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 2004: 21: 267.
45. Cozzo C, Larkin J Jr, Caton AJ. Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 2003: 171: 5678.
46. Esplugues E, Sancho D, Vega-Ramos J et al. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med 2003: 197: 1093.
47. Zingoni A, Palmieri G, Morrone S et al. CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur J Immunol 2000: 30: 644.
48. Zorn E, Kim HT, Lee SJ et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005: 106: 2903.